Bleeding Disorder News and Research

RSS
Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency

FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency

Rare bleeding disorder misdiagnosed

Rare bleeding disorder misdiagnosed

First mobile application is now available for clinicians to diagnose bleeding disorders

First mobile application is now available for clinicians to diagnose bleeding disorders

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration presents IB1001 PK data for treatment of hemophilia B

Inspiration presents IB1001 PK data at European haemophilia congress

Inspiration presents IB1001 PK data at European haemophilia congress

Scientist identifies natural signaling molecule that can prevent Hemophilia A

Scientist identifies natural signaling molecule that can prevent Hemophilia A

Octapharma supports development of 'Diagnosis and Management of von Willebrand Disease' CE supplement

Octapharma supports development of 'Diagnosis and Management of von Willebrand Disease' CE supplement

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

rVWF safe in patients with type 3 and severe type 1 von Willebrand disease, suggests interim study data

rVWF safe in patients with type 3 and severe type 1 von Willebrand disease, suggests interim study data

No evidence of toxicity in hemophilia B patients enrolled in gene therapy trial

No evidence of toxicity in hemophilia B patients enrolled in gene therapy trial

CSL Behring launches next generation HeliTrax System for Apple's devices

CSL Behring launches next generation HeliTrax System for Apple's devices

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products

Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products

Bayer launches unique fitness program for hemophilia A children

Bayer launches unique fitness program for hemophilia A children

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

Octapharma USA launches wilate replacement therapy Web site for von Willebrand Disease

Octapharma USA launches wilate replacement therapy Web site for von Willebrand Disease

Researchers develop new animal model for studying hemophilia A

Researchers develop new animal model for studying hemophilia A

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval